1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma

• Henry Miles Prince,
• Chunrui Li,
• Hongmei Jing,
• Fang Ren,
• Zhen Cai,
• Li Bao,
• Peter Tan,
• Sorab Jehangir Shavaksha,
• Qingsong Yin,
• Peilong Lai,
• Qiumei Deng,
• Mingfei Zhang,
• Shuqi Zeng,
• Qiaoyang Lu,
• Chengjun Jiang,
• Danqing Wu,
• Jianqing Mi

Affiliations

Henry Miles Prince

3Epworth Healthcare, Richmond, VIC, Australia

Chunrui Li

5Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei Province, China

Hongmei Jing

8Peking University, Third Hospital, Beijing, Beijing, China

Fang Ren

11Shanghai EpimAb Biotherapeutics, Shanghai, Shanghai, China

Zhen Cai

6The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, Zhejiang Province, China

Li Bao

7Beijing Jishuitan Hospital, Beijing, Beijing, China

Peter Tan

1One Clinical Research (OCR), Nedlands, Western Australia, Australia

Sorab Jehangir Shavaksha

2Sunshine Coast Haematology and Oncology Clinic (SCHOC), Buderim, QLD, Australia

Qingsong Yin

4The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhenzhou, Henan Province, China

Peilong Lai

9Guangdong Provincial People’s Hospital, Guangzhou, Guangdong Province, China

Qiumei Deng

10Epimab Biotherapeutics, Shanghai, CA, Namibia

Mingfei Zhang

11Shanghai EpimAb Biotherapeutics, Shanghai, Shanghai, China

Shuqi Zeng

11Shanghai EpimAb Biotherapeutics, Shanghai, Shanghai, China

Qiaoyang Lu

11Shanghai EpimAb Biotherapeutics, Shanghai, Shanghai, China

Chengjun Jiang

11Shanghai EpimAb Biotherapeutics, Shanghai, Shanghai, China

Danqing Wu

11Shanghai EpimAb Biotherapeutics, Shanghai, Shanghai, China

Jianqing Mi

12Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, Shanghai, China